Co-Authors
This is a "connection" page, showing publications co-authored by Christopher Daugherty and Mark J. Ratain.
Connection Strength
1.168
-
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000 May-Jun; 22(3):6-14.
Score: 0.190
-
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491.
Score: 0.167
-
User beware: we need more science and less art when measuring financial toxicity in oncology. J Clin Oncol. 2015 Apr 20; 33(12):1414-5.
Score: 0.133
-
The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014 Oct 15; 120(20):3245-53.
Score: 0.126
-
A study of informed consent (IC), age, and cognitive performance (CP) among advanced cancer patients (acp) in phase I trials. J Clin Oncol. 2008 May 20; 26(15_suppl):9523.
Score: 0.083
-
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8.
Score: 0.081
-
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007 Aug 10; 25(23):3488-94.
Score: 0.079
-
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol. 2007 Feb 10; 25(5):548-54.
Score: 0.076
-
Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
Score: 0.042
-
Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997 Jun 01; 126(11):892-7.
Score: 0.039
-
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484.
Score: 0.037
-
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May; 13(5):1062-72.
Score: 0.034
-
Pushing the envelope: informed consent in phase I trials. Ann Oncol. 1995 Apr; 6(4):321-3.
Score: 0.033
-
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst. 1994 Nov 16; 86(22):1685-93.
Score: 0.033
-
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
Score: 0.016